Anteris Technologies Global Corp(AVR) - 2025 Q1 - Quarterly Report

Financial Performance - Net sales for the three months ended March 31, 2025, were $0.6 million, a decrease of$0.2 million (27%) compared to $0.8 million for the same period in the prior year, primarily due to lower demand for tissue products [106]. - Cost of products sold during the same period was$0.2 million, a decrease of $0.3 million (56$0.5 million for the same period in the prior year, attributed to reduced net sales and changes in product mix [107]. - Loss before income taxes from continuing operations was $21.9 million for Q1 2025, an increase of$5.8 million (36%) compared to Q1 2024 [112]. - Net cash used in operating activities during Q1 2025 was $21.5 million, an increase of$6.0 million (38%) compared to $15.5 million in Q1 2024 [119]. - Cash and cash equivalents as of March 31, 2025, were$49.0 million, down from $70.5 million as of December 31, 2024 [115]. - The accumulated deficit as of March 31, 2025, was$298.3 million, up from 276.4 million as of December 31, 2024 [114]. Research and Development - R&D expenses increased to 16.5 million, an increase of $4.9 million (42$11.6 million for the same period in the prior year, driven by upscaling manufacturing capabilities and preparatory activities for the Pivotal Trial [108]. - The company anticipates requiring substantial additional funds to achieve long-term goals and complete R&D of current products [116]. - The company expects to continue incurring substantial losses in the near future until regulatory approval is obtained for its products [116]. Operational Activities - The company has treated over 100 patients with the DurAVR® THV system across the United States, Canada, and Europe as of March 31, 2025 [85]. - The company is expanding global manufacturing capacity to support the PARADIGM Trial, aiming to increase capacity to at least three times the 2024 levels [96]. Capital and Financing - The initial public offering on December 12, 2024, raised net proceeds of $80.0 million after deducting underwriting discounts and expenses [86]. - Capital commitments relating to property leases were$1.3 million as of March 31, 2025 [115]. - The company had commitments to purchase $0.2 million of plant and equipment as of March 31, 2025 [124]. Other Income and Expenses - Selling, general and administrative expenses decreased to$5.7 million, a reduction of $0.8 million (13$6.5 million for the same period in the prior year, mainly due to lower costs associated with the initial public offering [109]. - Other non-operating income decreased to $0.1 million, a decline of$0.3 million (78%) compared to $0.4 million for the same period in the prior year, primarily due to the recognition of additional government grants in the previous year [110]. - Net foreign exchange losses were$0.2 million, a change of $1.5 million (118$1.2 million for the same period in the prior year, influenced by fluctuations in foreign exchange rates [111]. Cash Flow Activities - Net cash provided by investing activities during Q1 2025 was $1.1 million, a change of$1.8 million (255%) compared to cash outflows of $0.7 million in Q1 2024 [120]. - Net cash used in financing activities during Q1 2025 was$1.1 million, a change of $2.6 million (170$1.6 million in Q1 2024 [121].